Clinical Trials Logo

Inflammation clinical trials

View clinical trials related to Inflammation.

Filter by:

NCT ID: NCT00229034 Completed - Sepsis Clinical Trials

Effect of APC and Epo on the Inflammatory Response During Sepsis

Start date: September 2005
Phase: N/A
Study type: Observational

An observational study to determine the effect of APC and Epo in reducing the systemic inflammatory response during severe sepsis.

NCT ID: NCT00227487 Active, not recruiting - Inflammation Clinical Trials

Intestinal Inflammation and Carbohydrate Digestion in Autistic Children

Start date: October 2005
Phase: N/A
Study type: Interventional

The purpose of the study is to find correlations between non-invasive fecal tests of intestinal inflammation and macro- and microscopic evaluation of duodenal and colonic histology, disaccharidase activity, and intestinal permeability in children with autism.

NCT ID: NCT00223704 Completed - Surgery Clinical Trials

Bradykinin Receptor Antagonism During Cardiopulmonary Bypass

BRAC
Start date: May 2006
Phase: Phase 2/Phase 3
Study type: Interventional

Each year over a million patients worldwide undergo cardiac surgery requiring cardiopulmonary bypass (CPB). CPB is associated with significant morbidity including the transfusion of allogenic blood products, inflammation and hemodynamic instability. In fact, approximately 20% of all blood products transfused are associated with coronary artery bypass grafting procedures. Transfusion of allogenic blood products is associated with well-documented morbidity and increased mortality after cardiac surgery. Enhanced fibrinolysis contributes to increased blood product transfusion in the perioperative period. The current proposal tests the central hypothesis that endogenous bradykinin contributes to the hemodynamic, fibrinolytic and inflammatory response to CPB and that bradykinin receptor antagonism will reduce hypotension, inflammation and transfusion requirements. In SPECIFIC AIM 1 we will test the hypothesis that the fibrinolytic and inflammatory response to CPB differ during ACE inhibition and angiotensin II type 1 receptor antagonism. In SPECIFIC AIM 2 we will test the hypothesis that bradykinin B2 receptor antagonism attenuates the hemodynamic, fibrinolytic, and inflammatory response to CPB. In SPECIFIC AIM 3 we will test the hypothesis that bradykinin B2 receptor antagonism reduces the risk of allogenic blood product transfusion in patients undergoing CPB. These studies promise to provide important information regarding the effects of drugs that interrupt the RAS and generate new strategies to reduce morbidity in patients undergoing CPB.

NCT ID: NCT00221052 Completed - Obesity Clinical Trials

Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men

Start date: June 2005
Phase: N/A
Study type: Interventional

Overweight increases the risk to develop chronic diseases including type-2 diabetes and cardiovascular disease. The low-grade inflammatory status often seen in overweight subjects is thought to play an important role in disease development. The purpose of this study is to determine the role of inflammation on glucose metabolism and insulin resistance. In this study the effect of the anti-inflammatory treatment diclofenac on markers of inflammation and on parameters of glucose metabolism will be studied.

NCT ID: NCT00211471 Terminated - Clinical trials for Central Retinal Vein Occlusion

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

Start date: March 2002
Phase: Phase 2
Study type: Interventional

To provide use of Anecortave Acetate Sterile Suspension of 15mg for a series of five patients with rubeosis iridis. Rubeosis iridis refers to neovascularization of the iris. It is caused by a number of conditions which include, but are not limited to severe diabetic retinopathy, central retinal vein occlusion, chronic inflammation, and infection. Anecortave acetate is an angiostatic, experimental drug that is being tested to prevent the growth of blood vessels under the retina in patients with age-related macular degeneration (AMD). Therefore, it is logical to apply the usage of Anecortave to patient’s with rubeosis iridis in order to reduce the neovascularization stimulus and cause the regression of the abnormal iris vessels.

NCT ID: NCT00207038 Completed - Asthma Clinical Trials

Airway Inflammation in Swimmers

Start date: September 2005
Phase: N/A
Study type: Observational

Studies have shown that the prevalence of respiratory symptoms, airway hyperresponsiveness (AHR) and asthma is high and increasing in elite athletes. The inflammation seen in the airways of elite athletes might differ from the inflammation seen in the airways of "ordinary" asthmatics and it might represent a different kind of asthma. The primary purposes are 1. To investigate the type of airway inflammation in young swimmers. 2. To investigate the acute changes in airway inflammation after a short training session.

NCT ID: NCT00203684 Recruiting - Asthma Clinical Trials

Mentored Patient-Oriented Research Career Development Award

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

Asthmatics have inflammation in the large airways (tubes through which air travels in and out of the lungs). The large airways are located in the central lung. New research shows that asthmatics also have inflammation in the small airways. The small airways are located in the peripheral lung (the parts of the lung away from the central lung). Until now, most of the inhaled medications available have been made up of big particles that never reach the peripheral lung. The purpose of this study is to try to measure the level of inflammation in the peripheral lung in asthmatics and see if this inflammation can be decreased with different types of inhaled corticosteroids. The investigators will check airway inflammation before and after use of an inhaled corticosteroid that has a large particle size and should only reach the large airways (Flunisolide-CFC), and before and after use of an inhaled, small particle corticosteroid that should reach both the large and small airways (Flunisolide-HFA). Subjects will make 6 study visits over two phases of the study. In the first phase, the investigators will collect baseline information about subjects while they are using placebo (inactive substance). In the second phase, subjects will take either the large or small particle corticosteroid. Visits will involve questionnaires and various tests measuring lung function (such as spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be measured as an indication of inflammation. Subjects will also measure and make note of lung function at home twice daily using a peak expiratory flow meter. Two of the visits will involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue samples without surgery. Another two of the visits will involve the use of high resolution computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the lungs.

NCT ID: NCT00195364 Completed - Clinical trials for Rheumatoid Arthritis

Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain

Start date: July 2003
Phase: Phase 4
Study type: Observational

The purpose of this study is to evaluate long-term safety of etanercept in patients with rheumatoid arthritis who successfully have completed open-label safety study 0881A1-301-EU

NCT ID: NCT00190125 Not yet recruiting - Inflammation Clinical Trials

The Influences of Malnutrition and Inflammation Complex Syndrome in Hemodialysis Patients

Start date: n/a
Phase: N/A
Study type: Observational

The purpose of this study is to explore the severity of malnutrition and inflammation in Taiwanese hemodialysis patients.

NCT ID: NCT00183001 Completed - Inflammation Clinical Trials

Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification

Start date: October 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if supplemental vitamin K will reduce age-related bone loss in elderly men and women above that achieved by supplementation.